HHorinouchi· @HHorinouchi · X·· 2 天前评分60
正文 · 机器翻译
🆙#ESMO26 优选论文：#LCSM 非转移性 🔥ASTRIDE：Serplulimab 或 Atezolizumab 联合化疗治疗美国广泛期小细胞肺癌患者的随机试验 🎙️ @drgandara 🔢3809O 🎯Serplulimab 的 OS 数值上优于 Atezolizumab 🎯mOS 12.4 vs 10.2m，HR 0.82；24个月 OS 32.2% vs 17.6% ☑️NCT05468489 🔗 https://t.co/grEfaUbJVf @OncoAlert @Larvol @myESMO @IASLC
热度 8 · 5 赞 · 0 回复 · 3 转发
会议摘要
NCT05468489NCT05468489按 - **标题 / Title：** To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC 对上
- **标题 / Title：** To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC读摘要原文 →来源：HHorinouchi · x.com